Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immulina
- Development stage
- Preclinical
- Lead developer
- University of Mississippi
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Immulina is a commercially available oral dietary supplement derived from the cyanobacterium *Arthrospira platensis* (also known as *Spirulina* or *Limnospira*). It is enriched with Braun-type lipoproteins, which act as potent Toll-like receptor 2 (TLR2) agonists. This activation leads to the enhancement of innate and adaptive immune responses, including increased natural killer cell activity, T-helper cell proliferation, and the production of pro-inflammatory cytokines like TNF-alpha, IL-1beta, IL-6, and IFN-gamma. Immulina has been investigated for its potential to enhance host resilience to viral infections, mitigate influenza illness, modulate immune measures, and address conditions like Post Acute COVID-19 Syndrome and immune senescence in elderly individuals. Preclinical studies also suggest potential anti-cancer and anti-allergic inflammatory effects.
- Brand names
- Immulina
- Other names
- Immulina TMImmulina®
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Immulina.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immulina.